Biotechnology: analysis of 18 November 2026

Back to the Chronology · Current news in this section

Photo from Alphabet’s Isomorphic Labs raises $5B to accelerate drug discovery with AI, SiliconANGLE AI

Analysis

Alphabet's Isomorphic Labs closes a $5 billion raise, the biggest biotech cash infusion of the year, as AI-driven drug discovery draws capital even while late-stage results and regulatory decisions remain mixed.

The week was dominated by capital flows into AI-enabled drug discovery: Isomorphic Labs secured $5 billion led by Greenoaks and Sequoia with a 'significant' contribution from Alphabet, described as the two largest cash infusions in biotech this year, and Flagship committed £100 million to build 'AI-native platform companies' in the UK 156. Dealmaking by large pharma continued apace, with Lilly's $1.5 billion purchase of Calytrix marking its 15th announced acquisition of the year and J&J paying $2.2 billion for Ollin's vision-loss drug 2024. Regulators sent contrasting signals, approving Roche's breast cancer pill but refusing Summit's PD-1/VEGF drug ivonescimab over its failure to extend survival 417. Meanwhile, strong trial data from CG Oncology and Sellas contrasted with a STAT analysis noting that positive clinical results are not being uniformly rewarded by investors 8192123.

Key developments

  • Isomorphic's $5B raise anchors AI drug-discovery boom. Isomorphic Labs closed a $5 billion investment led by Greenoaks and Sequoia Capital, joined by more than half a dozen backers including parent Alphabet, which made a 'significant investment' [1]. BioPharma Dive notes this gives Isomorphic the two largest cash infusions in biotech this year, even as the wider AI industry faces turmoil [6]. It sits alongside Flagship's £100 million UK outpost for AI-native platform companies and trade commentary stressing that infrastructure and environment, not just models, determine whether AI pilots succeed [5][27][28]. 1562728
  • FDA splits: Roche approval, Summit rejection. The FDA cleared Roche's breast cancer pill Wilserdly, which analysts call a 'key first step' for a launch Roche says could become its top-selling product [4]. In contrast, the agency refused to overlook ivonescimab's failure to initially extend survival in a form of lung cancer, rejecting Summit's PD-1/VEGF drug and setting back its first chance at US approval, sending shares lower [17]. The decisions suggest the FDA is holding firm on survival endpoints in oncology even for closely watched mechanisms [17]. 417
  • Pharma buyout streak continues with Lilly and J&J. Lilly announced a $1.5 billion purchase of Calytrix, centred on a precision therapy for myeloproliferative neoplasms, its 15th announced acquisition this year and by far the most in the sector [24]. J&J committed $2.2 billion for Ollin's vision-loss drug, which could complement its eye-care franchise but faces a crowded, competitive market [20]. Lilly is also seeding startups, backing Seawolf (which disclosed an up to $1.2 billion Sanofi partnership) and a $100 million Versant-led gene therapy venture [26][30]. 20242630
  • Strong oncology data from CG Oncology and Sellas. CG Oncology's cretostimogene cut the risk of bladder cancer recurrence by 68% when given after surgery, far exceeding Wall Street expectations and lifting shares, with STAT suggesting the results may change how physicians treat certain patients [19][23]. Separately, Sellas' experimental blood cancer immunotherapy reduced the risk of death in a clinical trial [8]. Yet STAT notes the biotech rebound is not lifting all boats equally, with investors not consistently rewarding positive data [21]. 8192123
  • Sickle cell startup Marrow challenges gene therapy. Marrow launched with $173 million in venture funding, positioning its approach as a more accessible alternative to gene therapy and gene editing for sickle cell and beta thalassemia [9][10]. The pitch is a treatment as effective as gene therapy without its drawbacks, though the reports describe the entrepreneur's view rather than demonstrated clinical results [10]. It lands as the field confronts gene therapy's challenges, including a patient death in a brain-disease trial and a new $100 million startup targeting one of gene therapy's 'thorniest issues' [11][26]. 9101126
  • Gene therapy safety and delivery under scrutiny. After an unexpected patient death in a gene therapy trial aimed at crossing the blood-brain barrier, researchers report progress on better ways to mitigate risk [11]. A Nature Biotechnology analysis of FDA IND submissions from 1995 to 2025 shows rapid AAV growth over three decades and highlights common issues in submissions, while a CD7-targeted AAV variant enabled in vivo T and NK cell engineering [31][33]. New tools such as Superb-seq, which tracks on- and off-target Cas9 effects at single-cell resolution, could sharpen safety assessment [25]. 11253133

Themes

  • Capital concentrating in AI and platform plays. Investment is flowing heavily into AI-centred discovery and platform builders, from Isomorphic's $5 billion and Flagship's UK outpost to Novo Nordisk's use of Amazon Bedrock for manufacturing documentation [1][5][6][18]. Vendor commentary stresses that infrastructure, trust and traceability, not the models themselves, are the binding constraints [14][27][28]. 1561827
  • Big pharma as serial acquirer and venture backer. Lilly's 15 acquisitions this year plus its stakes in Seawolf and a Versant-led gene therapy startup, alongside J&J's Ollin deal and Sanofi's Seawolf partnership, show large companies sourcing innovation through both buyouts and early-stage funding [20][24][26][30]. This supports startup formation even as public-market reaction to clinical data remains selective [21]. 2021242630
  • Rethinking disease biology: immunity, microbiome, enhancers. Several items challenge established models, from ImmunoBrain's immunotherapy approach to Alzheimer's that departs from the amyloid-tau framework, to studies linking gut viral communities and bile-acid modification to IBS and longevity [2][7][15]. Enhancer-targeted CRISPR in autism organoids and genetic barcoding of transplanted stem cells likewise point to more nuanced mechanistic understanding [3][12]. 2371215

What to watch

  • Whether Summit can chart a regulatory path for ivonescimab after the FDA's rejection on survival grounds, and how Roche's Wilserdly launch progresses toward its stated top-seller ambition [4][17]. 417
  • How Isomorphic deploys its $5 billion and whether the AI-discovery capital surge translates into clinical candidates, given commentary that infrastructure and environment, not models, are the bottleneck [1][6][27][28]. 162728
  • Follow-up on gene therapy safety, including the brain-disease trial death and whether Marrow's non-genetic sickle cell approach produces data to match its positioning [9][10][11]. 91011
  • Safety scrutiny of Helus' psychedelic depression drug, which improved symptoms but reported a number of serious adverse events, and the market's response to CG Oncology's and Sellas' positive readouts amid uneven investor rewards [8][19][21][22]. 8192122
Stories this analysis is based on (28)
  1. Alphabet’s Isomorphic Labs raises $5B to accelerate drug discovery with AI SiliconANGLE AI
  2. Beyond Amyloid and Tau: Alzheimer’s Drug Developer Sees Early Clinical Success for Immunotherapy-Based Approach GEN (Genetic Engineering & Biotechnology News)
  3. Genetic Barcoding Reveals How Pre-Bone Marrow Transplant Conditioning Impacts Immune System Regeneration GEN (Genetic Engineering & Biotechnology News)
  4. Roche breast cancer pill cleared by FDA BioPharma Dive
  5. STAT+: Flagship opens biotech-creation outpost in the U.K. STAT Biotech
  6. AI drugmaker Isomorphic restocks with $5B fundraise BioPharma Dive
  7. Mapping the Hidden Viral Communities of the Human Gut Microbiome GEN (Genetic Engineering & Biotechnology News)
  8. STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial STAT Biotech
  9. Marrow sets out to challenge genetic medicines for severe blood diseases BioPharma Dive
  10. STAT+: With $173 million, new startup takes aim at sickle cell STAT Biotech
  11. STAT+: After death in gene therapy trial for a brain disease, progress is reported STAT Biotech
  12. Enhancer-Targeted CRISPR Turns Up Healthy Gene Copy in Autism Organoid Model GEN (Genetic Engineering & Biotechnology News)
  13. Gut Microbome and Bile Acid Modification Linked with Longevity GEN (Genetic Engineering & Biotechnology News)
  14. Summit shares fall as FDA rejects closely watched PD-1/VEGF drug BioPharma Dive
  15. Novo Nordisk modernizes manufacturing process documents with Amazon Bedrock AgentCore AWS Machine Learning Blog
  16. CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial BioPharma Dive
  17. J&J bets $2.2B on Ollin’s vision loss drug BioPharma Dive
  18. STAT+: Biotech’s rebound isn’t lifting all boats equally STAT Biotech
  19. STAT+: Helus’ psychedelic drug improved depression in study but faces safety questions STAT Biotech
  20. STAT+: Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence STAT Biotech
  21. Lilly adds to buyout streak with $1.5B purchase of startup Calytrix BioPharma Dive
  22. Single-Cell Method Reveals On- and Off-Target Effects of Cas9 Edits on Gene Expression GEN (Genetic Engineering & Biotechnology News)
  23. STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues STAT Biotech
  24. The infrastructure decisions that will enable tomorrow’s biggest breakthroughs BioPharma Dive
  25. Your AI pilots aren’t stalling because of the AI – they’re stalling because of your environment BioPharma Dive
  26. Big-name investors pour $100M into DNA therapeutics developer Seawolf BioPharma Dive
  27. A CD7-targeted AAV variant enables efficient T and NK cell engineering in vivo Nature Biotechnology
  28. A comprehensive analysis of CBER experience with AAV gene therapy IND submissions Nature Biotechnology

Written by Claude Fable 5.1 (Anthropic), based on 34 recent headlines and excerpts in this section, 2d ago. AI analysis can misread or miss things: the numbers link to the original reporting, which is the authority.